RTP Mobile Logo
Breast Cancer Update: Surgical Edition, Issue 1, 2018 (Video Program)
Released December 2018

Proceedings from video interviews with Drs Harold J Burstein and Terry Mamounas on the treatment of breast cancer. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for breast and general surgeons, surgical oncologists, surgical fellows and other healthcare providers involved in the treatment of breast cancer (BC).

    OVERVIEW OF ACTIVITY
    BC continues to be one of the most rapidly evolving fields in medical oncology. Historically, surgery has been the primary mode of treatment for early BC. The complexity of the diagnostic, surgical and medical management of this disease, however, has escalated because of numerous advances in novel technologies and available adjunctive therapies. Hence, the multifaceted treatment of BC now requires the input of an interdisciplinary group of expert care providers, and this paradigm shift has created the challenge of ensuring that knowledge of major clinical advances in local and systemic therapy is effectively disseminated among all members of the cross-functional team. To bridge the gap between research and patient care, Breast Cancer Update for Surgeons uses one-on-one interviews with leading BC investigators to efficiently distill the latest research developments so they may be incorporated into clinical practice as appropriate. By providing access to cutting-edge data and expert perspectives, this CME program assists breast surgeons in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Implement a long-term clinical plan for the management of early-stage HER2-positive BC, incorporating existing, recently approved and emerging targeted treatments.
    • Consider published data to guide the use of biomarkers and genomic assays in assessing risk and individualizing therapy for patients with hormone receptor-positive BC in the neoadjuvant and adjuvant settings.
    • Develop an evidence-based approach to the management of the axilla in patients with localized BC and a positive sentinel lymph node biopsy.
    • Individualize the selection of treatment for patients with hormone receptor-positive BC, including the use of endocrine, biologic and chemotherapeutic agents.
    • Counsel appropriately selected patients with BC about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABS MAINTENANCE OF CERTIFICATION
    This activity provides Category 1 CME that may be used as self-assessment credit toward Part 2 of the American Board of Surgery MOC Program. It is the responsibility of each individual to remain apprised of the current requirements for his or her board-specific MOC Program. For more information about the ABS MOC Program, visit www.absurgery.org.

    HOW TO USE THESE CME ACTIVITIES
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BCUS118/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/BCUS118/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BCUS118/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/BCUS118.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Terry Mamounas, MD, MPH
    Medical Director, Comprehensive Breast Program
    Orlando Health UF Health Cancer Center
    Professor of Surgery, University of Central Florida
    Orlando, Florida

    Advisory Committee and Consulting Agreements: bioTheranostics Inc, Genentech, Genomic Health Inc, Roche Laboratories Inc; Speakers Bureau: Genentech, Genomic Health Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genomic Health Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2018
    Expiration date: December 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Harold J Burstein, MD, PhD

Interview with Terry Mamounas, MD, MPH

Select Publications